Thrombosis News and Research RSS Feed - Thrombosis News and Research

Thrombosis is the formation or presence of a thrombus (blood clot) inside a blood vessel.
New study finds efficacy of novel intravenous blood thinner in women

New study finds efficacy of novel intravenous blood thinner in women

Percutaneous coronary intervention (PCI) is a staple of modern day medicine in which cardiologists place a stent in a blood vessel around the heart in order to restore blood flow in people with heart disease. Blood thinners allow for the procedure to be completed with a reduced risk of certain complications such as clots. [More]
Wyss Institute scientists develop better assay for testing hemostasis

Wyss Institute scientists develop better assay for testing hemostasis

Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University have devised a better assay for testing blood's clotting tendency, also known as hemostasis, which could one day prove lifesaving in a variety of clinical situations in which a patient's health is jeopardized by abnormal blood coagulation and platelet function. [More]
Mount Sinai cardiologist honored with Spain's highest health distinction

Mount Sinai cardiologist honored with Spain's highest health distinction

Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, was honored by the Government of Spain with the highest health distinction awarded in Spain. [More]
Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), is the first to demonstrate that women on blood thinners can take estrogen-containing contraception or hormone replacement therapy without an increased risk of blood clots or uterine bleeding. [More]
Study: Preoperative use of blood-thinning drugs associated with decreased risk of blood clots

Study: Preoperative use of blood-thinning drugs associated with decreased risk of blood clots

Among patients undergoing major cancer operations, the preoperative use of blood-thinning drugs such as heparin does not increase rates of major bleeding or transfusions, and is associated with a decreased risk of blood clots, according to new study results published online in the Journal of the American College of Surgeons ahead of print publication early next year. [More]
Study reveals pathogenetic role of miR-125a in pulmonary hypertension

Study reveals pathogenetic role of miR-125a in pulmonary hypertension

Pulmonary hypertension is an umbrella term used for many conditions that all result in elevation of the pulmonary arterial pressure. Of interest, many of these completely different clinical and pathophysiological entities result in a final common pathway of vasoconstriction, micro thrombosis and vascular remodelling. [More]
New technology may facilitate early detection of sickle cell disease for infants in developing countries

New technology may facilitate early detection of sickle cell disease for infants in developing countries

Researchers from Seidman Cancer Center at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine presented new research findings this weekend at the 57th Annual Meeting of the American Society of Hematology in Orlando. [More]
XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the results from their real-world study XALIA showing that, in people with deep vein thrombosis (DVT), the rates of major bleeding and recurrent blood clots for XARELTO (rivaroxaban) in routine clinical practice were generally consistent with those observed in Phase 3 research. [More]
New model of arterial thrombus formation is similar to popular video game

New model of arterial thrombus formation is similar to popular video game

A group of biophysicists, including representatives from MIPT, has developed a mathematical model of arterial thrombus formation, which is the main cause of heart attacks and strokes. [More]
Boston Scientific obtains FDA approval, CE Mark for AngioJet ZelanteDVT catheter to treat DVT

Boston Scientific obtains FDA approval, CE Mark for AngioJet ZelanteDVT catheter to treat DVT

Boston Scientific has received United States (U.S.) Food and Drug Administration approval and CE Mark for the AngioJet ZelanteDVT thrombectomy catheter to treat deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins. [More]
LSP, Bristol-Myers Squibb announce immuno-oncology collaboration

LSP, Bristol-Myers Squibb announce immuno-oncology collaboration

LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced today a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need. [More]
Birmingham researchers identify how Salmonella infections can lead to life-threatening thrombosis

Birmingham researchers identify how Salmonella infections can lead to life-threatening thrombosis

Researchers from the University of Birmingham have, for the first time, identified how Salmonella infections that have spread to our blood and organs can lead to life-threatening thrombosis. [More]
Negative impact of high-fat diet on red blood cells may promote development of cardiovascular disease

Negative impact of high-fat diet on red blood cells may promote development of cardiovascular disease

University of Cincinnati researchers have discovered the negative impact a high fat diet has on red blood cells and how these cells, in turn, promote the development of cardiovascular disease. [More]
New data validates use of ActiveCare DVT prophylaxis compression system following total joint replacement surgery

New data validates use of ActiveCare DVT prophylaxis compression system following total joint replacement surgery

Medical Compression Systems, Inc. (MCS), today announced new data further validating the use of the ActiveCare DVT prophylaxis compression system following total joint replacement procedures. [More]
New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients. [More]
Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study evaluating ISIS-FXIRx in patients with end-stage renal disease (ESRD) on hemodialysis. In May 2015, Isis entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of clotting disorders. [More]
Nanofiber hydrogel infused with snake venom may stop bleeding, protect wounds

Nanofiber hydrogel infused with snake venom may stop bleeding, protect wounds

A nanofiber hydrogel infused with snake venom may be the best material to stop bleeding quickly, according to Rice University scientists. [More]
FDA grants accelerated approval to Praxbind (idarucizumab)

FDA grants accelerated approval to Praxbind (idarucizumab)

The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects. [More]
Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding. [More]
LEADERS FREE clinical trial demonstrates superior safety, efficacy for BioFreedom compared with bare-metal stent

LEADERS FREE clinical trial demonstrates superior safety, efficacy for BioFreedom compared with bare-metal stent

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, announced today that the LEADERS FREE clinical trial demonstrated superior safety and efficacy for BioFreedom compared with a bare-metal stent (BMS). [More]
Advertisement
Advertisement